From
this update from Dr Ron Tompkins (bolding mine):
--
In 2020, OMF secured a $1 million grant to launch the first year of an international, multi-year study across the five OMF funded Collaborative Research Centers (CRC). The aim of this study is to examine Post-COVID Syndrome transitioning to ME/CFS. We are actively
working to raise an additional $2 million for years two and three of the study.
Project Overview
The ability to monitor the development of ME/CFS from a known viral infection is unprecedented to date and crucial to our understanding of the disease. The CRCs have initiated the collection, extensive testing and analysis of COVID-19 patient samples.
My colleague, Dr. Jonas Bergquist, Director of the Uppsala Collaborative Research Center, has shared that
as of February 2021:
“
We have now done proteomics (the large-scale study of proteins)
and metabolomics (an analysis of the metabolism)
in cerebrospinal fluid (CSF)
and blood plasma from about 40 Intensive Care Unit COVID-19 patients. Our next step will be the large-scale metabolomic study of plasma from a larger cross-section of less severe COVID-19 patients (where we have no possibility to collect CSF) not admitted into the ICU.
In parallel, we are performing
CSF proteomics and blood plasma metabolomics in around 50 Herpes Simplex Encephalitis patients (a rare infection with a related neurological disorder). The data from this cohort will provide a valuable baseline for neuroinflammation (an inflammatory response within the brain). As we are also running both CSF and plasma analysis from ME/CFS patients in the same investigation, we have a unique opportunity to
compare and learn from COVID-19, HSE and ME/CFS patients.”
Example of tests to be performed:
- Autoantibodies
- Proteomics
- Leukocyte Genomics
- Immune Cell Profiling
- Metabolomics
- Micro RNA
- Extracellular DNA (Viral reactivation and Mitochondrial DNA)
- Microvesicles and viral sequencing
We hope that our studies in blood and CSF samples will help us be able to identify proteins and large molecules (e.g., antibodies) and small molecules that appear or disappear as ME/CFS develops, helping to advance our understanding of the biological triggers for this disease.
--